Pharmaceutical Technology lists ten of the most popular tweets in cardiovascular in November 2019, based on data from GlobalData’s Influencer Platform. The top tweets were chosen from influencers as tracked...
10 December 2019 Analysis
3 December 2019 Company News
Drug maker Novartis could become a leader in CVD therapeutics after purchasing The Medicine Company and its Atherosclerotic cardiovascular disease therapy Inclisiran for $9.7bn Novartis recently announced plans to complete...
27 November 2019 Deal News
Kyowa Kirin has announced an expansion of its collaboration with specialised biotech Ardelyx regarding the latter’s novel cardiorenal-focused therapies.
18 November 2019 News
Novartis has announced its heart failure drug Entresto (sacubitril/valsartan) causes a greater reduction in heart failure hospitalisation and cardiovascular (CV) deaths compared to valsartan alone in women with heart failure...
15 November 2019 News
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
6 November 2019 Comment
AstraZeneca has targeted and continues to target multiple indications and related comorbidities to expand the therapeutic reach of Farxiga.
24 October 2019 Influencers
Pharmaceutical Technology lists the top five terms tweeted in cardiovascular in Q3 2019, based on data from GlobalData’s Influencer Platform.
22 October 2019 Comment
Cardiovascular diseases are responsible for almost half of all deaths in the World Health Organization European region.
8 October 2019 Comment
The inhaled PDE4 inhibitor showed a larger reduction of moderate to severe exacerbations in a subgroup of patients with chronic bronchitis.
27 September 2019 Analysis
Although CV disease is the main cause of death globally, it is a particularly significant issue in developing countries where there are more challenges to accessing medication. One solution to...